Effect of gastric acid suppressants and prokinetics on peritoneal dialysis-related peritonitis

Table 2 Acid-suppressive therapy and other medications in peritonitis group and no peritonitis group n (%)

	Peritonitis group	No peritonitis group	P value
	(n = 61)	(n = 59)
Use of PPIs	6 (9.8)	10 (16.9)	0.252
≤ 7 d	5 (8.2)	4 (6.8)	0.691
8-30 d	0 (0.0)	1 (1.7)
> 30 d-1 yr	1 (1.6)	5 (8.5)
No use	55 (90.2)	49 (83.1)
Use of H2Bs	15 (24.6)	4 (6.8)	0.011
≤ 7 d	7 (11.5)	3 (5.1)	0.041
8-30 d	1 (1.6)	0 (0.0)
> 30 d-1 yr	7 (11.5)	1 (1.7)
No use	46 (75.4)	55 (93.2)
Use of other antacids	4 (6.6)	3 (5.1)	1.000
≤ 7 d	3 (1.9)	1 (1.7)	0.472
8-30 d	1 (0.0)	1 (1.7)
> 30 d-1 yr	0 (1.9)	1 (1.7)
No use	57 (96.2)	56 (94.9)
Use of prokinetics	20 (32.8)	18 (30.5)	0.789
≤ 7 d	11 (18.0)	10 (16.9)	0.712
8-30 d	2 (3.3)	0 (0.0)
> 30 d-1 yr	7 (11.5)	8 (13.6)
No use	41 (67.2)	41 (69.5)
Use of immunosuppressants	4 (6.6)	3 (5.1)	1.000
≤ 7 d	2 (3.3)	1 (1.7)	0.610
8-30 d	0 (0.0)	0 (0.7)
> 30 d-1 yr	2 (3.3)	2 (3.4)
No use	57 (93.4)	56 (94.9)

PPIs: Proton pump inhibitors; H2B: H2-blockers.